Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.41), $0.08 worse than the analyst estimate of ($1.33). Revenue for the quarter came in at $44 million versus the consensus estimate of $40.17 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.